175 related articles for article (PubMed ID: 33969275)
1. Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial.
Harrison CN; Schaap N; Vannucchi AM; Kiladjian JJ; Jourdan E; Silver RT; Schouten HC; Passamonti F; Zweegman S; Talpaz M; Verstovsek S; Tang D; Abraham P; Lord-Bessen J; Rose S; Guo S; Liao W; Mesa RA
Hemasphere; 2021 May; 5(5):e562. PubMed ID: 33969275
[TBL] [Abstract][Full Text] [Related]
2. Patient-reported Effects of Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2, on Myelofibrosis-related Symptoms and Health-related Quality of Life in the Randomized, Placebo-controlled, Phase III JAKARTA Trial.
Mesa RA; Schaap N; Vannucchi AM; Kiladjian JJ; Passamonti F; Zweegman S; Talpaz M; Verstovsek S; Rose S; Abraham P; Lord-Bessen J; Tang D; Guo S; Ye X; Harrison CN
Hemasphere; 2021 May; 5(5):e553. PubMed ID: 33969273
[TBL] [Abstract][Full Text] [Related]
3. Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial.
Mesa RA; Gotlib J; Gupta V; Catalano JV; Deininger MW; Shields AL; Miller CB; Silver RT; Talpaz M; Winton EF; Harvey JH; Hare T; Erickson-Viitanen S; Sun W; Sandor V; Levy RS; Kantarjian HM; Verstovsek S
J Clin Oncol; 2013 Apr; 31(10):1285-92. PubMed ID: 23423753
[TBL] [Abstract][Full Text] [Related]
4. Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure.
Harrison CN; Schaap N; Vannucchi AM; Kiladjian JJ; Jourdan E; Silver RT; Schouten HC; Passamonti F; Zweegman S; Talpaz M; Verstovsek S; Rose S; Shen J; Berry T; Brownstein C; Mesa RA
Am J Hematol; 2020 Jun; 95(6):594-603. PubMed ID: 32129512
[TBL] [Abstract][Full Text] [Related]
5. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.
Harrison CN; Schaap N; Vannucchi AM; Kiladjian JJ; Tiu RV; Zachee P; Jourdan E; Winton E; Silver RT; Schouten HC; Passamonti F; Zweegman S; Talpaz M; Lager J; Shun Z; Mesa RA
Lancet Haematol; 2017 Jul; 4(7):e317-e324. PubMed ID: 28602585
[TBL] [Abstract][Full Text] [Related]
6. Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy.
Harrison CN; Mesa RA; Kiladjian JJ; Al-Ali HK; Gisslinger H; Knoops L; Squier M; Sirulnik A; Mendelson E; Zhou X; Copley-Merriman C; Hunter DS; Levy RS; Cervantes F; Passamonti F; Barbui T; Barosi G; Vannucchi AM
Br J Haematol; 2013 Jul; 162(2):229-39. PubMed ID: 23672349
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase-2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts.
Harrison CN; Schaap N; Vannucchi AM; Kiladjian JJ; Passamonti F; Zweegman S; Talpaz M; Verstovsek S; Rose S; Zhang J; Sy O; Mesa RA
Br J Haematol; 2022 Jul; 198(2):317-327. PubMed ID: 35476316
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of fedratinib in patients with myelofibrosis previously treated with ruxolitinib: primary analysis of FREEDOM trial.
Gupta V; Yacoub A; Mesa RA; Harrison CN; Vannucchi AM; Kiladjian JJ; Deeg HJ; Fazal S; Foltz L; Mattison RJ; Miller CB; Parameswaran V; Brown P; Hernandez C; Wang J; Talpaz M
Leuk Lymphoma; 2024 Jun; ():1-11. PubMed ID: 38838026
[TBL] [Abstract][Full Text] [Related]
9. Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis.
Bewersdorf JP; Jaszczur SM; Afifi S; Zhao JC; Zeidan AM
Cancer Manag Res; 2019; 11():10777-10790. PubMed ID: 31920387
[TBL] [Abstract][Full Text] [Related]
10. Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy.
Mesa R; Verstovsek S; Kiladjian JJ; Griesshammer M; Masszi T; Durrant S; Passamonti F; Harrison CN; Pane F; Zachee P; Zhen H; Jones MM; Parasuraman S; Li J; Côté I; Habr D; Vannucchi AM
Eur J Haematol; 2016 Aug; 97(2):192-200. PubMed ID: 26608702
[TBL] [Abstract][Full Text] [Related]
11. Real-world outcomes with fedratinib therapy in patients who discontinued ruxolitinib for primary myelofibrosis.
Passamonti F; Lou Y; Chevli M; Abraham P
Future Oncol; 2023 Nov; ():. PubMed ID: 37991002
[TBL] [Abstract][Full Text] [Related]
12. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
Harrington KJ; Ferris RL; Blumenschein G; Colevas AD; Fayette J; Licitra L; Kasper S; Even C; Vokes EE; Worden F; Saba NF; Kiyota N; Haddad R; Tahara M; Grünwald V; Shaw JW; Monga M; Lynch M; Taylor F; DeRosa M; Morrissey L; Cocks K; Gillison ML; Guigay J
Lancet Oncol; 2017 Aug; 18(8):1104-1115. PubMed ID: 28651929
[TBL] [Abstract][Full Text] [Related]
13. Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: results from the VISTA trial.
Delforge M; Dhawan R; Robinson D; Meunier J; Regnault A; Esseltine DL; Cakana A; van de Velde H; Richardson PG; San Miguel JF
Eur J Haematol; 2012 Jul; 89(1):16-27. PubMed ID: 22469559
[TBL] [Abstract][Full Text] [Related]
14. Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes.
Verstovsek S; Gotlib J; Gupta V; Atallah E; Mascarenhas J; Quintas-Cardama A; Sun W; Sarlis NJ; Sandor V; Levy RS; Kantarjian HM; Mesa RA
Onco Targets Ther; 2013; 7():13-21. PubMed ID: 24368888
[TBL] [Abstract][Full Text] [Related]
15. Health-related quality-of-life results from PALETTE: A randomized, double-blind, phase 3 trial of pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or after prior chemotherapy-a European Organization for research and treatment of cancer soft tissue and bone sarcoma group global network study (EORTC 62072).
Coens C; van der Graaf WT; Blay JY; Chawla SP; Judson I; Sanfilippo R; Manson SC; Hodge RA; Marreaud S; Prins JB; Lugowska I; Litière S; Bottomley A
Cancer; 2015 Sep; 121(17):2933-41. PubMed ID: 26033286
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy and safety of JAK inhibitor ruxolitinib in Chinese patients with myelofibrosis: results of a 1-year follow-up of A2202].
Jin J; Du X; Zhou DB; Li JM; Li JY; Hou M; Liu T; Wu DP; Hu Y; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2016 Oct; 37(10):858-863. PubMed ID: 27801315
[TBL] [Abstract][Full Text] [Related]
17. Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial.
Coens C; Suciu S; Chiarion-Sileni V; Grob JJ; Dummer R; Wolchok JD; Schmidt H; Hamid O; Robert C; Ascierto PA; Richards JM; Lebbé C; Ferraresi V; Smylie M; Weber JS; Maio M; Bottomley A; Kotapati S; de Pril V; Testori A; Eggermont AMM
Lancet Oncol; 2017 Mar; 18(3):393-403. PubMed ID: 28162999
[TBL] [Abstract][Full Text] [Related]
18. Fedratinib in myelofibrosis.
Mullally A; Hood J; Harrison C; Mesa R
Blood Adv; 2020 Apr; 4(8):1792-1800. PubMed ID: 32343799
[TBL] [Abstract][Full Text] [Related]
19. The role of fedratinib for the treatment of patients with primary or secondary myelofibrosis.
Palmer J; Mesa R
Ther Adv Hematol; 2020; 11():2040620720925201. PubMed ID: 32477483
[TBL] [Abstract][Full Text] [Related]
20. Patient-reported Outcomes and Quality of Life in Anemic and Symptomatic Patients With Myelofibrosis: Results From the MOMENTUM Study.
Mesa RA; Harrison C; Palmer JM; Gupta V; McLornan DP; McMullin MF; Kiladjian JJ; Foltz L; Platzbecker U; Fox ML; Mead AJ; Ross DM; Oh ST; Perkins AC; Leahy MF; Kawashima J; Ro S; Donahue R; Gorsh B; Deheshi S; Verstovsek S
Hemasphere; 2023 Nov; 7(11):e966. PubMed ID: 37901848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
